Can Regeneron’s Odronextamab Stand Out With Better Safety?
Entering Crowded CD20 Bispecific Field
Presentation of diffuse large B-cell lymphoma data at ASH showed low rates of higher-grade cytokine release syndrome and no cases of ICANS.

Presentation of diffuse large B-cell lymphoma data at ASH showed low rates of higher-grade cytokine release syndrome and no cases of ICANS.